Search Result

Results for "

NAD(P)H oxidation

" in MedChemExpress (MCE) Product Catalog:

By Targets:	NADPH Oxidase (4) 11β-HSD (1) Acetyl-CoA Carboxylase (1) Akt (1) Aldehyde Dehydrogenase (ALDH) (1) Aminotransferases (Transaminases) (1) Apoptosis (2) Bcl-2 Family (1) Calcineurin (1) Caspase (1) Cathepsin (1) Cytochrome P450 (2) DNA/RNA Synthesis (1) Endogenous Metabolite (7) ERK (1) Fatty Acid Synthase (FASN) (2) Flavivirus (1) FOXO (1) Fungal (2) Insulin Receptor (1) Isocitrate Dehydrogenase (IDH) (2) JAK (1) Methylenetetrahydrofolate Dehydrogenase (MTHFD) (1) Mitochondrial Metabolism (3) NO Synthase (7) PARP (2) Quinone Reductase (2) Reactive Oxygen Species (ROS) (3) Reference Standards (2) SHMT (1) STAT (1)
By Research Areas:	Cancer (9) Cardiovascular Disease (7) Infection (3) Inflammation/Immunology (9) Metabolic Disease (16) Neurological Disease (5)

By Targets:

NADPH Oxidase (4)

11β-HSD (1)

Acetyl-CoA Carboxylase (1)

Akt (1)

Aldehyde Dehydrogenase (ALDH) (1)

Aminotransferases (Transaminases) (1)

Apoptosis (2)

Bcl-2 Family (1)

Calcineurin (1)

Caspase (1)

Cathepsin (1)

Cytochrome P450 (2)

DNA/RNA Synthesis (1)

Endogenous Metabolite (7)

ERK (1)

Fatty Acid Synthase (FASN) (2)

Flavivirus (1)

FOXO (1)

Fungal (2)

Insulin Receptor (1)

Isocitrate Dehydrogenase (IDH) (2)

JAK (1)

Methylenetetrahydrofolate Dehydrogenase (MTHFD) (1)

Mitochondrial Metabolism (3)

NO Synthase (7)

PARP (2)

Quinone Reductase (2)

Reactive Oxygen Species (ROS) (3)

Reference Standards (2)

SHMT (1)

STAT (1)

By Research Areas:

Cancer (9)

Cardiovascular Disease (7)

Infection (3)

Inflammation/Immunology (9)

Metabolic Disease (16)

Neurological Disease (5)

Inhibitors & Agonists

Peptides

Natural
Products

Targets Recommended: NADPH Oxidase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-113324

NADPH 15+ Cited Publications	Endogenous Metabolite	Cancer
NADPH is a coenzyme of glutathione reductase (GR), thioredoxin reductase (TrxR) and NADPH oxidase (NOX), and participates in redox reactions as a hydrogen donor. NADPH has the characteristic of selectively participating in the regulation of cellular redox homeostasis. NADPH exerts antioxidant activity and resists reactive oxygen species (ROS) damage by providing reducing equivalents for the regeneration of glutathione (GSH) and thioredoxin (Trx); at the same time, it acts as a substrate of NOX to generate superoxide anions, mediating oxidative stress and immune response. NADPH participates in maintaining the intracellular reducing environment, biosynthesis and regulating gene expression (such as the Nrf2 pathway), and is mainly used in the study of oxidative stress-related diseases (such as cardiovascular diseases, neurodegenerative diseases, cancer) and immune regulation mechanisms .

HY-100986

L-NIO dihydrochloride 1 Publications Verification	NO Synthase	Cardiovascular Disease
L-NIO dihydrochloride is a potent, non-selective and NADPH-dependent *nitric oxide* synthase (NOS) inhibitor, with K_i**s of 1.7, 3.9, 3.9 μM for neuronal (nNOS), endothelial (eNOS), and inducible (iNOS), respectively . L-NIO dihydrochloride induces a consistentfocal ischemic infarctin rats .

HY-128895

KL1333 1 Publications Verification	Quinone Reductase Mitochondrial Metabolism	Metabolic Disease
KL1333, a derivative of β-lapachone, is an orally available NAD+ modulator. KL1333 reacts with NAD(P)H:quinone oxidoreductase 1 (NQO1) as a substrate, resulting in increases in intracellular NAD+ levels via NADH oxidation. KL1333 improves energy metabolism and mitochondrial dysfunction in MELAS fibroblasts. KL1333 protects against Cisplatin-induced ototoxicity in mouse cochlear cultures .

HY-125863

Glucose-6-phosphate dehydrogenase, Microorganism G6PD	Endogenous Metabolite	Metabolic Disease Cancer
Glucose-6-phosphate dehydrogenase, Microorganism (G6PD) is the rate-limiting enzyme of the pentose phosphate pathway. Glucose-6-phosphate dehydrogenase, Microorganism is a primary source of NADPH in antioxidant pathways, nitric oxide synthase, NADPH oxidase, cytochrome p450 systems, and others. Glucose-6-phosphate dehydrogenase, Microorganism is applicable in research related to diabetes, endothelial dysfunction, cancer, and cardiomyopathy .

HY-123962

G6PD activator AG1 5+ Cited Publications	NADPH Oxidase	Metabolic Disease
G6PD activator AG1 is a potent and selective glucose-6-phosphate dehydrogenase (G6PD) agonist with an EC50 of 3 μM. G6PD is an oxidoreductase that catalyzes the oxidation of glucose-6-phosphate to 6-phosphogluconolactone and the simultaneous reduction of NAD phosphate (NADP) to reduced NADP (NADPH). G6PD activator AG1 can reduce hemolysis of human erythrocytes .

HY-125862

Glutathione Reductase, baker's yeast EC 1.6.4.2; GR	Calcineurin Reactive Oxygen Species (ROS)	Cardiovascular Disease Neurological Disease
Glutathione reductase, baker's yeast (EC 1.6.4.2) is a reductase. Glutathione reductase, baker's yeast eliminates intracellular ROS. Glutathione reductase, baker's yeast reduces oxidized glutathione (GSSG) to reduced glutathione (GSH) using NADPH as an electron donor. Glutathione reductase, baker's yeast exerts antioxidant activity. Glutathione reductase is mainly used to study diseases associated with oxidative stress, such as Parkinson's disease and sickle cell anemia .

HY-124529

Lunularin	11β-HSD Endogenous Metabolite	Metabolic Disease Inflammation/Immunology Cancer
Lunularin is an inhibitor of 11β-hydroxysteroid dehydrogenase 1, with an IC₅₀ of 45.44 μM and a K_i of 35.8 μM against human 11β-HSD1, and an IC₅₀ of 17.39 μM and a K_i of 10.31 μM against rat 11β-HSD1. Lunularin upregulates the transcription levels of Sirt1 and Hmox1 genes in the liver. Lunularin reduces food intake and body weight gain, and decreases blood glucose levels in mice fed a high-fat diet. Lunularin inhibits LPS-induced TLR4-mediated NF-κB pathway activation and nitric oxide production. Lunularin inhibits the proliferation and colony formation of renal cancer and colon cancer cells, and exhibits cancer cell-specific cytotoxicity. Lunularin binds to the steroid-binding site of human 11β-HSD1 and the steroid/NADPH-binding region of rat 11β-HSD1, but does not inhibit 11β-HSD2 or mouse 11β-HSD1. Lunularin can be used in research related to diet-induced obesity, renal cancer, colorectal cancer, inflammatory diseases and metabolic syndrome .

HY-P2947

ALDH Aldehyde dehydrogenase (NAD(P))	Aldehyde Dehydrogenase (ALDH)	Others Cancer
ALDH (Aldehyde dehydrogenase (NAD(P))) catalyzes the oxidation of aldehydes into their corresponding carboxylic acids with the concomitant reduction of the cofactor NAD(P) into NAD(P)H, is often used in biochemical studies. The ALDHs are one of many enzyme systems the body utilizes to alleviate aldehyde stress .

HY-12119

GW274150 2 Publications Verification	NO Synthase	Neurological Disease Inflammation/Immunology
GW274150 is a potent, selective, orally active and NADPH-dependent inhibitor of human *inducible nitric oxide* synthase (iNOS) (IC₅₀=2.19 μM; K_d=40 nM) and rat iNOS (ED₅₀=1.15 μM). GW274150 also displays less potency for both humans or rats endothelial NOS (eNOS) and neuronal NOS (nNOS**). GW274150 exerts a protective role in an acute model of lung injury inflammation .

HY-W015422

1,5-Isoquinolinediol	PARP	Metabolic Disease
1,5-Isoquinolinediol is a potent PARP inhibitor, with an IC₅₀ of 0.18-0.37 μM. 1,5-Isoquinolinediol attenuates diabetes-induced NADPH oxidase-derived oxidative stress in retina .

HY-107586

Demethylasterriquinone B1 DAQ B1; L-783281; Dimethylasterriquinone	Insulin Receptor Akt NO Synthase NADPH Oxidase JAK STAT FOXO DNA/RNA Synthesis ERK Flavivirus	Cardiovascular Disease Infection Metabolic Disease Inflammation/Immunology
Demethylasterriquinone B1 (DAQ B1; L-783281) is an orally active insulin receptor (insulin receptor) agonist and AKT activator. By activating AKT, Demethylasterriquinone B1 upregulates the expression and activity of eNOS to increase NO production, while downregulating the expression of the *NADPH* oxidase subunit p22phox to reduce oxidative stress and improve vascular endothelial dysfunction in hypertensive rats. Demethylasterriquinone B1 combind with an AKT inhibitor targets the insulin signaling pathway to activate two antiviral pathways, RNA interference and JAK/STAT, in mosquitoes, thereby reducing Zika virus infection .

HY-P3186

Glucose dehydrogenase, recombinant Microorganisms	Endogenous Metabolite	Metabolic Disease
Glucose dehydrogenase, recombinant Microorganisms is a FDA-dependent oxidoreductase. Glucose dehydrogenase (GDH) catalyzes the oxidation of β-D-glucose to β-D-glucono-1,5-lactone with simultaneous reduction of the cofactor NADP ⁺ to NADPH or, to a lesser extent, NAD ⁺ to NADH. Glucose dehydrogenase (GDH) accepts both NAD ⁺ and NADP ⁺ as cofactors and can be used for the regeneration of NADH and NADPH .

HY-12119A

GW274150 phosphate 2 Publications Verification	NO Synthase	Neurological Disease Inflammation/Immunology
GW274150 phosphate is a potent, selective, orally active and NADPH-dependent inhibitor of human *inducible nitric oxide* synthase (iNOS) (IC₅₀=2.19 μM; K_d=40 nM) and rat iNOS (ED₅₀=1.15 μM). GW274150 phosphate displays less potency for both humans or rats endothelial NOS (eNOS) and neuronal NOS (nNOS**). GW274150 phosphate exerts a protective role in an acute model of lung injury inflammation .

HY-122940

Precocene II Ageratochromene	Endogenous Metabolite	Metabolic Disease
Precocene II (Ageratochromene) is a plant larva hormone antagonists that inhibits the biosynthesis of juvenile hormone. Precocene II inhibits corpora allata function and downregulates juvenile hormone levels, while exerting multiple effects including inducing precocious metamorphosis, forming macropterous morphs, inhibiting ovarian growth, producing cytotoxicity, disrupting insect development, and causing sterility and kidney damage. Precocene II blocks normal nymphal development, causes renal tubular damage and increases blood urea nitrogen levels, and also blocks juvenile hormone biosynthesis in vitro. Precocene II undergoes oxidative metabolism catalyzed by NADPH-dependent monooxygenase to generate a variety of metabolites. Precocene II can be applied in studies related to insect growth regulation and nephrotoxicity .

HY-W612338

9-Oxononanoic acid 9-ONA	Acetyl-CoA Carboxylase	Inflammation/Immunology
9-Oxononanoic acid (9-ONA) is an orally active acetyl-CoA carboxylase inhibitor. 9-Oxononanoic acid inhibits acetyl-CoA carboxylase via accumulation of long-chain acyl-CoA. 9-Oxononanoic acid increases carnitine palmitoyltransferase, isocitrate dehydrogenase and glucose 6-phosphate dehydrogenase activity to elevate β-oxidation and support NADPH (HY-113324) supplyactivity. 9-Oxononanoic acid stimulates phospholipase A2 activity via post-translational, non-transcriptional mechanisms. 9-Oxononanoic acid can be used for the research of atherothrombosis .

HY-P2993

Isocitrate dehydrogenase, Porcine heart ICDH; IDH	Isocitrate Dehydrogenase (IDH)	Metabolic Disease Cancer
Isocitrate dehydrogenase, Porcine heart (ICDH) is a citric acid or tricarboxylic acid cycle enzyme, is often used in biochemical studies. Isocitrate dehydrogenase catalyzes the oxidative decarboxylation of isocitrate to α-ketoglutarate and reduces NAD(P) ⁺ to NAD(P)H, it plays important roles in cellular metabolism .

HY-125863B

Glucose 6-phosphate dehydrogenase (yeast, recombinant) G6PD (yeast, recombinant)	Endogenous Metabolite	Cardiovascular Disease Metabolic Disease Cancer
Glucose 6-phosphate dehydrogenase (yeast, recombinant) is the rate-limiting enzyme of the pentose phosphate pathway and a major source of NADPH in antioxidant pathways, nitric oxide synthase, NADPH oxidase, and cytochrome P450 systems. Glucose 6-phosphate dehydrogenase helps cells resist oxidative stress and regulates metabolic rates. It holds potential for research in fields such as diabetes, endothelial dysfunction, cancer, and cardiomyopathy .

HY-100986B

L-NIO	NO Synthase	Cardiovascular Disease
L-NIO is a potent, non-selective and NADPH-dependent *nitric oxide* synthase (NOS) inhibitor, with K_i**s of 1.7, 3.9, 3.9 μM for neuronal (nNOS), endothelial (eNOS), and inducible (iNOS), respectively . L-NIO induces a consistentfocal ischemic infarctin rats .

HY-130579

Vinyl-L-NIO hydrochloride L-VNIO hydrochloride	NO Synthase NADPH Oxidase	Cardiovascular Disease Neurological Disease
Vinyl-L-NIO (L-VNIO) hydrochloride is a neuronal *nitric oxide* synthase (NOS) inhibitor with a rat K_i of 0.10 μM. Vinyl-L-NIO hydrochloride inhibits NADPH** oxidase activity, attenuates renal fibrosis, inflammation, oxidative stress indices, and albuminuria. Vinyl-L-NIO hydrochloride can be used for the research of parkinson's disease, migraine headache, and hypertension .

HY-172227

S-15176	Mitochondrial Metabolism	Cardiovascular Disease
S-15176 is an inhibitor of the mitochondrial permeability transition pore (PTP). S-15176 inhibits mitochondrial swelling induced by tert-butylhydroperoxide with an IC₅₀ value of 45.7 μM. S-15176 inhibits PTP opening, prevents mitochondrial membrane potential dissipation and NAD(P)H oxidation, and increases mitochondrial calcium loading capacity. S-15176 is promising for research of ischemia-reperfusion injury .

HY-N6237

Aspulvinone O	Aminotransferases (Transaminases) Apoptosis	Cancer
Aspulvinone O is a selective inhibitor of glutamate oxaloacetate aminotransferase GOT1. Aspulvinone O inhibits glutamine metabolism and reduces *NADPH* production, thereby inducing oxidative stress and apoptosis in pancreatic ductal adenocarcinoma (PDAC) cells. Aspulvinone O inhibits PDAC cell proliferation in vitro and tumor growth in xenograft models .

HY-114809

AL-1	Reactive Oxygen Species (ROS) NADPH Oxidase	Inflammation/Immunology Cancer
AL-1 is a potent O2 ^- generation inhibitor (IC₅₀ = 7.6 μM) through the inhibition of leukocytic NADPH oxidase. AL-1 inhibits 12-O-Tetradecanoylphorbol-13-acetate (TPA)-induced H₂O₂ production. AL-1 reduces tumor incidence in ICR mouse skin. AL-1 can be used for research on oxidative stress-related diseases including cancer .

HY-P2993A

Isocitrate dehydrogenase, Microorganism ICDH, Microorganism; IDH, Microorganism	Isocitrate Dehydrogenase (IDH)	Metabolic Disease
Isocitrate dehydrogenase, Microorganism (IDH) (EC 1.1.1.42) is a citric acid or tricarboxylic acid cycle enzyme, is often used in biochemical studies. Isocitrate dehydrogenase catalyzes the oxidative decarboxylation of isocitrate to α-ketoglutarate and reduces NAD(P) ⁺ to NAD(P)H, it plays important roles in cellular metabolism .

HY-128895A

KL1333 hydrochloride	Mitochondrial Metabolism Quinone Reductase	Metabolic Disease
KL1333 hydrochloride is an orally active NAD ⁺ modulator that reacts with NAD(P)H:quinone oxidoreductase 1 (NQO1) as a substrate, leading to increased intracellular NAD ⁺ levels through NADH oxidation. Elevated NAD ⁺ levels trigger activation of SIRT1 and AMPK, and subsequently activate PGC-1α. KL1333 hydrochloride improves energy metabolism and mitochondrial dysfunction in mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) fibroblasts. KL1333 hydrochloride protects against cisplatin-induced ototoxicity in mouse cochlear cultures .

HY-167879A

NPD6433	Fungal Fatty Acid Synthase (FASN)	Infection Inflammation/Immunology
NPD6433 is a triazenyl indole with broad-spectrum activity against all screening fungal strains. NPD6433 targets the enoyl reductase domain of fatty acid synthase 1 (Fas1), covalently inhibiting its flavin mononucleotide-dependent NADPH-oxidation activity and arresting essential fatty acid biosynthesis .

HY-167879

(Rac)-NPD6433	Fungal Fatty Acid Synthase (FASN)	Infection Inflammation/Immunology
(Rac)-NPD6433 is a racemate of NPD6433. NPD6433 is a triazenyl indole with broad-spectrum activity against all screening fungal strains. NPD6433 targets the enoyl reductase domain of fatty acid synthase 1 (Fas1), covalently inhibiting its flavin mononucleotide-dependent NADPH-oxidation activity and arresting essential fatty acid biosynthesis .

HY-113777

22-HDHA 22-Hydroxy Docosahexaenoic acid; 22-OH DHA	Cytochrome P450	Metabolic Disease
22-HDHA (22-Hydroxy Docosahexaenoic acid) is an oxidation product of docosahexaenoic acid. In vitro, it is formed upon incubation of rat liver microsomes with DHA and NADPH and also by the human cytochrome P450 (CYP) isoform CYP4F3B in BTI-TN-5B1-4 microsomes. Serum levels of 22-HDHA increase following dietary DHA supplementation in humans.

HY-12119B

GW274150 dihydrochloride	NO Synthase	Neurological Disease Inflammation/Immunology
GW274150 (dihydrochloride) is a potent, selective, orally active and NADPH-dependent inhibitor of human *inducible nitric oxide* synthase (iNOS) (IC₅₀=2.19 μM; K_d=40 nM) and rat iNOS (ED₅₀=1.15 μM). GW274150 (dihydrochloride) displays less potency for both humans or rats endothelial NOS (eNOS) and neuronal NOS (nNOS**). GW274150 (dihydrochloride) exerts a protective role in an acute model of lung injury inflammation .

HY-P0109

(S,S)-Z-FA-FMK	Cathepsin	Others
(S,S)-Z-FA-FMK is a cell-permeable, irreversible cathepsin B inhibitor. (S,S)-Z-FA-FMK blocks LPS-induced production of IL-1α and IL-1β. (S,S)-Z-FA-FMK can be used as a negative control for caspase-1 and caspase-2 inhibitors because it lacks an aspartic acid residue at the P1 position .

HY-P2759B

Thioredoxin Reductase (NADPH), Yeast	Endogenous Metabolite	Metabolic Disease
Thioredoxin reductase (TrxR/NTR), an enzyme belonging to the flavoprotein family of pyridine nucleotide-disulfide oxidoreductases. Thioredoxin reductase (TrxR), a component of the thioredoxin system, including thioredoxin (Trx) and NADPH, catalyzes the transfer of electrons from NADPH to Trx, acts as a reductant of disulfide-containing proteins and participates in the defense system against oxidative stresses.

HY-W015422R

1,5-Isoquinolinediol (Standard)	Reference Standards PARP	Metabolic Disease
1,5-Isoquinolinediol is a potent PARP inhibitor, with an IC50 of 0.18-0.37 μM. 1,5-Isoquinolinediol attenuates diabetes-induced NADPH oxidase-derived oxidative stress in retina .

HY-182284

Anticancer agent 310	Reactive Oxygen Species (ROS) Apoptosis Bcl-2 Family Caspase SHMT Methylenetetrahydrofolate Dehydrogenase (MTHFD) Cytochrome P450	Cancer
Anticancer agent 310 is an antitumor agent. Anticancer agent 310 releases nitric oxide to induce mitochondrial ROS burst, triggers mitochondrial dysfunction and activates the Bax/Bcl-2-Cyt c-Caspase-9/Caspase-3 apoptotic pathway. Anticancer agent 310 also reduces the levels of SHMT2 and MTHFD2, decreases the ratios of NADPH/NADP ⁺ and GSH/GSSG, thereby disrupting redox homeostasis and exacerbating intracellular ROS accumulation. Anticancer agent 310 can be used in research related to gastric cancer .

HY-122940R

Precocene II (Standard) Ageratochromene (Standard)	Others Reference Standards	Metabolic Disease
Precocene II (Standard) is the analytical standard of Precocene II (HY-122940). This product is intended for research and analytical applications. Precocene II (Ageratochromene) is a plant larva hormone antagonists that inhibits the biosynthesis of juvenile hormone. Precocene II inhibits corpora allata function and downregulates juvenile hormone levels, while exerting multiple effects including inducing precocious metamorphosis, forming macropterous morphs, inhibiting ovarian growth, producing cytotoxicity, disrupting insect development, and causing sterility and kidney damage. Precocene II blocks normal nymphal development, causes renal tubular damage and increases blood urea nitrogen levels, and also blocks juvenile hormone biosynthesis in vitro. Precocene II undergoes oxidative metabolism catalyzed by NADPH-dependent monooxygenase to generate a variety of metabolites. Precocene II can be applied in studies related to insect growth regulation and nephrotoxicity .

Cat. No.	Product Name	Target	Research Area